ノイラミニダーゼ阻害薬
WordNet
- a substance that retards or stops an activity
PrepTutorEJDIC
- 抑制する人(物) / 化学反応抑制剤
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/06/11 17:15:54」(JST)
[Wiki en表示]
Neuraminidase inhibitors are a class of drugs which block the neuraminidase enzyme. They are commonly used as antiviral drugs because they block the function of viral neuraminidases of the influenza virus, by preventing its reproduction by budding from the host cell. Oseltamivir (Tamiflu) a prodrug, Zanamivir (Relenza), Laninamivir (Inavir), and Peramivir belong to this class. Unlike the M2 inhibitors, which work only against the influenza A, neuraminidase inhibitors act against both influenza A and influenza B.[1][2][3][4] The neuraminidase inhibitors oseltamivir and zanamivir were approved in the US and Europe for treatment and prevention of influenza A and B.
The efficacy was highly debated in recent years.[citation needed] The benefits of neuraminidase inhibitors in those who are otherwise healthy do not appear to outweigh its risks.[citation needed] The combination of diagnostic uncertainty, the risk for virus strain resistance, possible side effects and financial cost outweigh the small benefits of oseltamivir or zanamivir for the prophylaxis and treatment of healthy individuals.[5] No benefit of treatment, on hospitalization, complications or risk of death has been found in randomized trials in those people at high risk for complications or the elderly.[5][6][7] The United States Centers for Disease Control continues to recommend the use of oseltamavir treatment for people at high risk for complications and the elderly and those at lower risk who present within 48 hours of first symptoms of infection.[8]
Common side effects include nausea and vomiting. For oseltamivir there were neuropsychiatric effects and for zanamivir bronchoconstriction occurred.
Contents
- 1 Specific neuraminidase inhibitors
- 2 Extracts and natural molecules
- 3 See also
- 4 References
Specific neuraminidase inhibitors
- Laninamivir
- Oseltamivir (Tamiflu)
- Peramivir
- Zanamivir (Relenza)
Extracts and natural molecules
- Cyanidin-3-sambubioside (Extract of Sambucus nigra, black elderberry)[9]
- Quercetin (not a Neuraminidase inhibitor)
See also
- Discovery and development of Neuraminidase Inhibitors
References
- ^ Smith, B. J.; McKimm-Breshkin, J. L.; McDonald, M.; Fernley, R. T.; Varghese, J. N.; Colman, P. M. (2002). "Structural Studies of the Resistance of Influenza Virus Neuramindase to Inhibitors". Journal of Medicinal Chemistry 45 (11): 2207. doi:10.1021/jm010528u. PMID 12014958.
- ^ Gubareva, Larisa V (2004). "Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors". Virus Research 103 (1-2): 199–203. doi:10.1016/j.virusres.2004.02.034.
- ^ This flash animation shows the mode of action of oseltamivir (Tamiflu). pharmasquare.org
- ^ Replication of influenza virus. mvm.ed.ac.uk
- ^ a b Coenen, B; Van Puyenbroeck, K; Verhoeven, V; Vermeire, E; Coenen, S (2013). "The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews". PLoS ONE 8 (4): e60348. Bibcode:2013PLoSO...860348M. doi:10.1371/journal.pone.0060348. PMC 3614893. PMID 23565231.
- ^ Ebell, MH; Call, M; Shinholser, J (April 2013). "Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials". Family practice 30 (2): 125–33. doi:10.1093/fampra/cms059. PMID 22997224.
- ^ Jefferson T, Jones MA, Doshi P et al. (April 2014). "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children". Cochrane Database Syst Rev 4: CD008965. doi:10.1002/14651858.CD008965.pub4. PMID 24718923.
- ^ "CDC Online Newsroom - "Have You Heard?" Archive: 2014 - Influenza A Variant Virus". cdc.gov.
- ^ Swaminathan K, Dyason JC, Maggioni A, von Itzstein M, Downard KM (2013). "Binding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometry". Anal Bioanal Chem. 405 (20): 6563–72. doi:10.1007/s00216-013-7068-x. PMID 23748498.
RNA virus antivirals (primarily J05, also S01AD and D06BB)
|
|
Hepatitis C |
- protease inhibitors
- Asunaprevir†
- Boceprevir
- Faldaprevir†
- Grazoprevir†
- Paritaprevir
- Ritonavir
- Telaprevir
- Simeprevir
- RNA polymerase inhibitors
- NS5A inhibitors
- ACH-3102†
- Daclatasvir
- Deleobuvir§
- Elbasvir†
- Ledipasvir
- MK-3682
- MK-8408
- Samatasvir
- Ombitasvir
combinations (Ombitasvir/paritaprevir/ritonavir)
|
|
Picornavirus |
|
|
Anti-influenza agents |
- adamantane derivatives/M2 inhibitors (Amantadine
- Rimantadine)
- neuraminidase inhibitors/release phase (Oseltamivir
- Zanamivir
- Peramivir, Laninamivir†)
|
|
Multiple/general |
Interferon |
- Interferon alfa 2b
- Peginterferon alfa-2a
|
|
Multiple/unknown |
- BCX4430
- Ribavirin#/Taribavirin†
- Moroxydine
- Favipiravir
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of viral disease
|
|
Description |
|
|
Disease |
- Systemic
- Cutaneous
- Zoster
- Human papillomavirus
- Zoonotic
- Symptoms and signs
|
|
Treatment |
|
|
|
Pharmacology: enzyme inhibition
|
|
Class |
- Competitive inhibition
- Uncompetitive inhibition
- Non-competitive inhibition
- Suicide inhibition
- Mixed inhibition
|
|
Substrate |
Oxidoreductase (EC 1) |
- 1.1 Aldose reductase
- HMG-CoA reductase
- 1.5 Dihydrofolate reductase
- 1.17 Xanthine oxidase
- Ribonucleotide reductase
|
|
Transferase (EC 2) |
- 2.1 COMT
- Thymidylate synthase
- 2.5 Dihydropteroate synthetase
- Farnesyltransferase
- 2.7 Nucleotidyltransferase
- Integrase
- Reverse transcriptase
- Protein kinase
|
|
Hydrolase (EC 3) |
- 3.1 Phosphodiesterase
- Acetylcholinesterase
- Ribonuclease
- 3.2 Polygalacturonase
- Neuraminidase
- Alpha-glucosidase
- 3.4 Protease: Exopeptidase
- Dipeptidyl peptidase-4
- ACE
- Endopeptidase
- Trypsin
- Renin
- Matrix metalloproteinase
- 3.5 Histone deacetylase
- Beta-lactamase
|
|
Lyase (EC 4) |
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
- van der Vries E1, Ip DK2, Cowling BJ2, Zhang JD3, Tong X4, Wojtowicz K5, Schutten M1, Boucher CA1.
- The Journal of infectious diseases.J Infect Dis.2016 Jan 15;213(2):183-90. doi: 10.1093/infdis/jiv375. Epub 2015 Jul 9.
- BACKGROUND: Little is known about how influenza infections caused by B/Victoria and B/Yamagata virus lineages compare with respect to disease course and susceptibility to antiviral therapy.METHODS: Data from patients with influenza B infections from the first 5 years (2009-2013) of the prospective I
- PMID 26160744
- Use of neuraminidase inhibitors for prophylaxis and treatment of pandemic influenza: summary of a Faculty of Public Health meeting.
- Haroon S1, Middleton J2, Milne E3.
- Journal of public health (Oxford, England).J Public Health (Oxf).2015 Dec 29. pii: fdv196. [Epub ahead of print]
- On 15th December 2014, a meeting was held at the Faculty of Public Health (FPH) to gain views and where possible consensus on the prophylactic use among the general population of neuraminidase inhibitors (NIs) for pandemic influenza. These perspectives were to be used to help inform the FPH's positi
- PMID 26715256
- Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models.
- Lian W1, Fang J1, Li C1, Pang X1, Liu AL2,3,4, Du GH5,6,7.
- Molecular diversity.Mol Divers.2015 Dec 21. [Epub ahead of print]
- Neuraminidase (NA) is a critical enzyme in the life cycle of influenza virus, which is known as a successful paradigm in the design of anti-influenza agents. However, to date there are no classification models for the virtual screening of NA inhibitors. In this work, we built support vector machine
- PMID 26689205
Japanese Journal
- 抗インフルエンザウイルス薬 : 新規薬剤を中心に (特集 新しい治療薬と呼吸器感染症診療の展開)
- A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza
- NABESHIMA Shigeki,KASHIWAGI Kenichiro,AJISAKA Kazuhiko,MASUI Shinta,TAKEOKA Hiroaki,IKEMATSU Hideyuki,KASHIWAGI Seizaburo
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 18(4), 534-543, 2012-08-01
- NAID 10030948165
Related Pictures
★リンクテーブル★
[★]
- 関
- blocker、depressant、suppressant